Extended-Release Methylphenidate

Phase 1

Extended-Release Methylphenidate is one of 51 therapeutic programs targeting Sickle Cell Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Sickle Cell DiseaseRecruiting

Sickle Cell DiseasePhase 1

Recruiting

Competition

Competitive Landscape

98 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Campath

GGenzyme, a Sanofi Company

Phase 3

13 2

Ritalin

Novartis

Phase 3

2 3

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 4

Toradol

JJavelin Pharmaceuticals

Phase 3

2 5

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

1 6

Fludara

Sanofi

Phase 2

9 7

Cellcept

Roche

Phase 2

6 8

PIASKY

Roche

Phase 3

2 9

Tepadina

Jazz Pharmaceuticals

Phase 2

4 10

Rapamune

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Sickle Cell Disease

NCT07226219

Clinical

Trials by Indication[1]

Sickle Cell Disease1 trial

Pilot Trial of Stimulant Treatment to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07226219·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Extended-Release Methylphenidate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Extended-Release Methylphenidate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: SSt. Jude Children's Research Hospital

Extended-Release Methylphenidate

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Sickle Cell Disease1 trial

References

Drug Info

Quick Facts

Related News